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Abstract
Background: Rectal cancer is a highly prevalent disease which needs a multidisciplinary approach to be treated. The absence of specific 
protocols implies a significant and unjustifiable variability among the different professionals involved in this disease.
The purpose is to develop a clinical pathway based on the analysis process and aims to reduce this variability and to reduce   unnecessary 
costs.
Methods: We created a multidisciplinary team with contributors from every clinical area involved in the diagnosis and treatment in this 
disease. We held periodic meetings to agree on a protocol based on the best available clinical practice guidelines. Once we had agreed 
on the protocol, we implemented its use as a standard in our institution. Every patient older than 18 years who was diagnosed with rectal 
cancer was considered a candidate to be treated via the pathway.
Results: We evaluated 48 patients during the course of this study. Every parameter measured was improved after the implementation of 
the pathway, except the proportion of patients with 12 nodes or more analysed.
The perception that our patients had about this project was very good.
Conclusions: Clinical pathways are needed to improve the quality of health care. This kind of project helps reduce hospital costs and 
optimizes the use of limited resources. On the other hand, unexplained variability is also reduced, with consequent benefits for the 
patients.
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Introduction
One concern after rectal cancer surgery is the high 
local  recurrence  rate.  It  has  also  been  recognised 
that 20%–40% of rectal cancer patients continue to 
develop distant metastases and die.1 The majority of 
patients with nonmetastatic rectal cancer are candi-
dates  for  an  aggressive  multimodal  approach  with 
curative intent and in these cases, preoperative stag-
ing is critical in determining which patients should be 
offered neoadjuvant therapy.2
The objective of treatment in rectal cancer is to 
decrease rate of recurrence, which is the most fre-
quent cause of mortality in these patients, and also 
to increase the survival rate.2 In recent years, many 
papers have been published that show the relevance 
of  neoadjuvant  treatment,  with  chemoradiotherapy 
decreasing the rate of local recurrence and, in some 
cases, increasing survival.3–5
Despite the fact that surgery is still an elective aspect 
of treating rectal cancer,1 the management of this disease 
should be performed by a multidisciplinary team, with 
contributions by surgeons, oncologists, pathologists,6,7 
medical and radiation radiologists, and gastroenterolo-
gists.2 This is the only way to obtain the best results not 
just for survival but also for quality of life.
This has also been a way to achieve the goals estab-
lished by the modern concept of quality in   healthcare.8 
But it is not always easy to create a work group com-
posed  of  every  specialist  involved  in  patient  care. 
Another difficulty is obtaining a consensus among the 
different specialists.9
Clinical pathways are healthcare plans in which 
the whole process of the disease from the diagnosis is 
described, including the responsibilities every profes-
sional has with the patient.9–11
Rectal cancer is one of the more complex tumoral 
diseases because of the need of multiple specialists to 
take part in its diagnosis and treatment.9 This means 
that  coordination  among  different  clinical  units  is 
necessary, which is often lacking. This fact requires 
us to develop a way to involve every specialist in a 
multidisciplinary team to avoid delays between dif-
ferent phases of the process and to avoid clinical vari-
ability among the different professionals involved. In 
this context, it seems to be relevant to create a clinical 
pathway and to implement it.2
Our study aims to describe the results before and 
after the process of elaborating a clinical pathway 
and the improvements obtained in the patients’ care 
parameters six months after its implementation.
Methods
We carried out this project during the second half of 
2009 and 2010 in our institution. The work consisted 
of developing, step by step, a clinical pathway in   rectal 
cancer. We chose this disease because of the high unex-
plained clinical variability we detected in a previous 
project we had carried out. This project (analysing the 
process) consisted of a retrospective cross-sectional 
study  of  44  patients  consecutively  diagnosed  with 
rectal cancer. The data showed a significant variabil-
ity in the process of diagnosis and treatment, related 
not only to the type of diagnostic tools but also to the 
waiting time to go on into the process, and to the treat-
ments and sequence of treatments they received. On 
the other hand, we had also detected a high variability 
in the contents of pathological reports and the profes-
sional  perception  of  poor  information  given  to  the 
patient and family about the process.
Once  the  schedule  of  activities  and  protocol  of 
this project were approved by the local Ethical Com-
mittee, we began to schedule many multidisciplinary 
meetings  with  representative  members  from  every 
clinical unit. Both authors coordinated the team and 
the progressive development of the clinical pathway.
Once the pathway was drafted, we tried to imple-
ment it with contributions from the leaders of our 
institution. Every patient older than 18 years diag-
nosed with rectal cancer after drafting the pathway 
was included in it.
To analyse the results, we used specific indicators 
created for this clinical pathway and our results were 
compared to a previous series of patients analyzed 
before the implementation of this pathway.
We hypothesized that the application of our project 
would obtain at least a 20% reduction in the clinical 
variability after six months of implementation and, on 
the other hand, would provide a high level of patient 
satisfaction and a good perception of quality of care, or an 
increase of 20% in the diagnostic procedures performed.
We analyzed the clinical effectiveness, real com-
pliance with the agreed goals and patient satisfaction 
once had been included in the clinical pathway.
We did a comparison of the evaluated parameters 
between the periods before and after implementation 
of this clinical pathway. We applied statistical analyses A clinical pathway in rectal cancer
Clinical Medicine Insights: Oncology 2010:4  113
using  the  Mann–Whitney  U  -test  and    considered 
P , 0.05 as statistically significant.
Results
Before  clinical  pathway  was  implemented,  we 
observed and identified several areas candidates to be 
improved, as shown in Table 1.
Six  months  after  the  implementation,  we  had 
recruited 48 patients according to selection criteria. The 
aim of our study was not the evaluation of the patient 
characteristics so we have not evaluated these in our 
study.
The pathological reports were improved by taking 
the information we agreed upon at the multidisciplinary 
meetings into account (see Table 2). The greatest benefits 
were seen in the information related to TNM (tumor, 
nodes,  metastases)  classification  classification  and 
about vascular invasion (see Table 3). Both parameters 
were clearly improved and we have demonstrated a 
clear statistical significance (P , 0.05).
Before  our  project  was  implemented,  many 
pathologists used to write the Dukes classification in 
their reports and the others used TNM. But after several 
meetings, the consensus was clear: TNM would be 
the only classification to use in our institution and this 
decision was complied with totally.
A  similar  process  was  followed  and  a  similar 
result  has  been  obtained  in  the  area  of  vascular 
invasion. However, we did not manage to make any 
improvements  before  and  after  implementing  the 
new protocol regarding rate of mention of number of 
nodes analysed or isolated.
Another relevant change has been the growing use 
of  chemoradiotherapy  as  a  neoadjuvant  treatment. 
Before the new pathway, this therapy was applied for 
just 2% of the patients but after the implementation, 
the percentage was 71%. Meanwhile, short courses of 
radiotherapy have been eliminated from our protocol. 
Both results were statistically significant.
Practically  all  time  intervals  between  different 
phases of the process have considerably improved 
and shortened, mainly in the parameters related to 
the time between first diagnostic tool and results, and 
also time to treatment.
One of the most important results we obtained was 
that the use of MRI during the preoperative stage of 
the disease has increased greatly, 10 times higher than 
previous use (P = 0.002).
Finally, anal sphincter preservation has increased 
and translates into surgeons being aware about the 
benefits of the neoadjuvant and treatment by multidis-
ciplinary teams, though this difference was not statis-
tically significant. Indirectly, this point may increase 
the quality of life of rectal cancer patients.
Two patients were evaluated but not included in this 
study because of avoidable causes. These were igno-
rance about the clinical pathway, although it was pre-
sented in a multidisciplinary meeting, or because many 
doctors did not want to participate in this project.
One notable finding highlighted an aspect of care 
that appeared to deteriorate after implementation of 
the pathway. This is the proportion of the patients with 
Table 1. Standards of quality determined by the clinical 
pathway committee members.
Aspect of care % of cases with 
this data missing 
n = 44 
Information
Pathological report 
histological grade 3%
Size 38%
Margins  21%
TNM classification  49%
nodes analysed 
not mentioned  0%
Isolated 0%
,12  67%
,4  11%
neoadjuvant treatment
hypofractionated radiotherapy  1%
Chemoradiotherapy 0%
Table  2.  Appropriate  interval  time  for  procedures,  as 
agreed upon by the workgroup.
procedures  expected time
Time from the first visit to colonoscopy  15 days
Time interval from colonoscopy to 
receiving pathological results 
7 days
Time from pathological diagnosis to 
first treatment 
15 days
Time from the end of preoperative 
treatment to surgery 
4–6 weeks
Time from colonoscopy to the end of 
diagnostic tests
15 days
MrI is performed  30%
Anal sphincter-saving procedure is 
performed 
60%Uña and López-Lara
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rectal cancer but with less than 12 nodes analysed. We 
do not have a reasonable explanation for this fact but it 
may be related to the small number of patients included 
in the study when we were writing the research.
We analysed also the patient´s satisfaction with the 
process and we achieved good results that showed a 
very  high  satisfaction  rate  with  every  parameter 
  evaluated (see Table 4).
Discussion and conclusions
Rectal cancer remains a frequent disease with vari-
able clinical results.1 Improving these results is a very 
important challenge at the moment.2 With this aim, 
we performed a pilot study to evaluate the improve-
ments obtained after implementing a clinical pathway 
in our institution.
We obtained positive results from the pilot study, so 
we planned to complete the project with the development 
of different clinical pathways related to every subpro-
cess in this disease, such as surgery protocols or care 
after surgery. We also intend to complete the study by 
including survival data once a reasonable period of 
time has passed after the implementation.
We  have  been  continuing  to  recruit  patients  to 
obtain more confident results after a great number of 
patients have been studied.
Although we would have liked to have a previous 
study of patient satisfaction before the implementa-
tion of our institutional pathway, unfortunately, we 
had not performed one before. Because of this, we 
cannot know if our new clinical pathway can improve 
Table 3. Improvement in the evaluated parameters after implementing clinical pathway.
parameter Before pathway 
n = 44 (%)
After pathway 
n = 48 (%)
P
pathology report poor in 
histological grade 23 0 nS
Size 58 0 0.011
Margins 41 0 0.030
TnM 69 0 0.003
Vascular invasion 79 0 0.001
nodes analysed not mentioned 16 0 nS
nodes isolated 19 0 nS
nodes ,12 analysed 87 90 nS
nodes ,4 31 0 0.030
neoadjuvant treatment
hypofractionated radiotherapy 31 0 0.03
Chemoradiotherapy 2 71 0.003
Appropiate interval between procedures
Time to colonoscopy 20 100 0.003
Time to results after biopsy 18 100 0.002
Time to first treatment 27 100 0.005
Time to surgery after the end of treatment 43 100 0.026
Time to end of diagnostic tests 23 44 nS
MrI performed as preoperative staging tool 9 90 0.002
Anal sphincter preservation 40 65 nS
Abbreviation: NS, not significant.
Table 4. Patients’ satisfaction after the implementation of 
this clinical pathway.
survey n = 48 % of patients 
answering yes
Do you think that the time to first 
treatment is adequate?
80%
Are you satisfied with the information 
you received during the process?
60%
Do you consider the length of hospital 
stay to be adequate?
100%
Do you think that the care and 
assistance you received was of high 
quality?
80%
Are you satisfied with the clinical 
attention you received?
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patient satisfaction, as we have no way of comparing 
satisfaction before and after implementation.
We can conclude that this clinical pathway has 
been positive to our patients and our institution, based 
on the improvements it has brough.
The development of a clinical pathway is a privilege 
and it is only possible in hospitals with a high degree of 
knowledge about clinical management and with profes-
sionals who are aware of the relevance of multidisci-
plinary teams. This is also the only way to achieve the 
highest levels of excellence in clinical cancer care.
Although cost has not been analyzed the percep-
tion we have so far since after the implementation of 
this pathway is that it could reduce the costs associ-
ated withthe clinical variability demonstrated before 
the implementation. These costs related to the high 
rate of diagnostic tools used without any clinical sig-
nificance, the absence of a protocol which could regu-
late the number and type of analyses performed, or 
the length of hospital stay, or the different surgical 
procedures or chemotherapy and radiotherapy treat-
ment given to the patients. This point is highly signif-
icant, given the current economic crisis and the lack 
of resources. This justifies a second project aimed 
towards obtaining a solid conclusion.
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